Last reviewed · How we verify
pirarubicin and cyclophosphamide
Pirarubicin is an anthracycline that intercalates into DNA and inhibits topoisomerase II, while cyclophosphamide is an alkylating agent that cross-links DNA, together inducing cancer cell death.
Pirarubicin is an anthracycline that intercalates into DNA and inhibits topoisomerase II, while cyclophosphamide is an alkylating agent that cross-links DNA, together inducing cancer cell death. Used for Breast cancer (as part of chemotherapy regimen), Various solid tumors and hematologic malignancies.
At a glance
| Generic name | pirarubicin and cyclophosphamide |
|---|---|
| Sponsor | Hebei Medical University Fourth Hospital |
| Drug class | Anthracycline and alkylating agent combination |
| Target | DNA (topoisomerase II for pirarubicin; DNA alkylation for cyclophosphamide) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Mechanism of action
Pirarubicin, a derivative of daunorubicin, intercalates between DNA base pairs and inhibits topoisomerase II, preventing DNA unwinding and causing double-strand breaks in rapidly dividing cells. Cyclophosphamide is a nitrogen mustard alkylating agent that forms covalent cross-links in DNA, preventing replication and transcription. This combination targets cancer cells through complementary mechanisms of DNA damage.
Approved indications
- Breast cancer (as part of chemotherapy regimen)
- Various solid tumors and hematologic malignancies
Common side effects
- Myelosuppression
- Nausea and vomiting
- Alopecia
- Cardiotoxicity
- Hemorrhagic cystitis
Key clinical trials
- Phase II Exploratory Study of Toripalimab Combined With SBRT in HER2-Negative Breast Cancer Patients With Insensitivity to Neoadjuvant Chemotherapy (PHASE2)
- FMD and Neoadjuvant Chemo-immunotherapy in TNBC (PHASE2)
- A Study of QL1706 Combined With Short-Cycle Anthracyclines or Taxanes for the Treatment of Early-Stage TNBC (PHASE1)
- Arsenic Trioxide With MAPK Inhibitors and Chemotherapy for Stage 4/M Neuroblastoma (PHASE2)
- Modified BFM-95 Regimen as First-Line Chemotherapy in Adults With T- Lymphoblastic Lymphoma (PHASE2)
- A Phase II Study of Rituximab, Chidamide, Zanubrutinib-induced and CHOP Therapy (PHASE2)
- Anlotinib Combined With Chemotherapy and Neoadjuvant Therapy for Hormone Receptor-positive HER-2 Negative Breast Cancer (PHASE2)
- Adjuvant Albumin-bound Paclitaxel Versus Taxanes in Breast Cancer: a Real-world Study (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: